Thiopurine Management
Phenotypes a patient to aid in individualizing a starting dose of thiopurines. Ordering prior to initiating therapy provides information as an aid for effective dosing, which may achieve maximum efficacy with minimized toxicity.
Sample insurance correspondence for PROMETHEUS® TPMT Enzyme
TPMT Enzyme is a laboratory-developed test that was developed, and analytically and clinically validated by Prometheus Laboratories Inc. under federal Clinical Laboratory Improvement Amendments (CLIA) guidelines, and is performed exclusively in our high complexity CLIA certified (05D0917432) and College of American Pathologists (CAP) accredited (6805501) clinical laboratory. As a laboratory developed test, it has not been cleared or approved by the US FDA. The test may be covered by one or more US pending or issued patents – see prometheuslabs.com/patents. Prometheus is a registered trademark of Prometheus Laboratories Inc, San Diego, California. All other trademarks or service marks are the property of their respective owners. This material is provided for general information purposes only, as an educational service for healthcare providers. It is not intended as a substitute for medical advice and/or consultation with a physician.